Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Atara Biotherapeutics Inc., 3 years.
Atara Biotherapeutics Inc.
Director
ADC Therapeutics SA
Director · Chief Executive Officer
Chief executive roles
ADC Therapeutics SA
· Chief Executive Officer
Since January 2024
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | ADC Therapeutics SA | Grant or award | +675,000 | — | — |
| Feb 13, 2026 | ADC Therapeutics SA | Grant or award | +900,000 | $3.99 | $3,591,000 |
| Feb 13, 2026 | ADC Therapeutics SA | Shares withheld for tax | −103,231 | $3.99 | $411,892 |
| Dec 6, 2025 | ADC Therapeutics SA | Shares withheld for tax | −233,146 | $3.29 | $767,050 |
| Jun 10, 2025 | Atara Biotherapeutics Inc. | Grant or award | +7,828 | — | — |
| May 6, 2025 | ADC Therapeutics SA | Shares withheld for tax | −26,758 | $1.29 | $34,518 |
| Feb 13, 2025 | ADC Therapeutics SA | Grant or award | +650,000 | $1.61 | $1,046,500 |
| Dec 6, 2024 | ADC Therapeutics SA | Shares withheld for tax | −238,343 | $3.13 | $746,014 |
| May 7, 2024 | ADC Therapeutics SA | Open-market sale | −29,731 | $4.48 | $133,195 |
| Mar 31, 2024 | Atara Biotherapeutics Inc. | Grant or award | +150,000 | — | — |
| May 31, 2023 | Atara Biotherapeutics Inc. | Grant or award | +57,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.